TrialClinical pharmacokinetics2016

Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.

Min Zhu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.